ResMed Inc (FRA:RME)
€ 201.5 0 (0%) Market Cap: 29.97 Bil Enterprise Value: 30.83 Bil PE Ratio: 33.89 PB Ratio: 7.00 GF Score: 97/100

Resmed Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 04:45PM GMT
Release Date Price: €145
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

This session, we welcome from ResMed, Rob Douglas, COO; and David Pendarvis, Global legal Counsel from the company. Thank you for your time today, gentlemen. What we'll start with is an introduction from Rob, and then we'll go to Q&A. Please enter your questions in your browser, if you're connected directly, and I'll endeavor to read your questions out.

So with that, thank you for your time today, gentlemen. And Rob, I'll throw to you for some opening remarks.

Robert A. Douglas
ResMed Inc. - President & COO

Great. Thanks, Sean. Thanks for having us here. For everyone listening, we did distribute a brief slide deck with just a few summary statistics on it, if you want to have a look at that and a safe harbor statement.

For those of you who don't know ResMed, we're the world leader in the -- including sleep apnea and other chronic diseases like COPD and asthma. Our focus really is on treatment outside of the hospital and as I'll explain in a second, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot